MPM Capital Limited Partnership
MPM Capital Limited Partnership firm targets biotechnology, specialty pharmaceutical, and medical technology companies. With more than $2 billion of committed capital in four funds, it invests in all stages of a firm's development, typically offering between $5 million and $50 million per transaction, and takes a long-term approach. MPM Capital's portfolio includes about 60 firms, including Affymax, AVEO Pharmaceuticals, Oxagen, and Surface Logix. Most of MPM Capital's investments are in US concerns, but the company also seeks opportunities in Europe, and more recently, Asia and Australia.
Contact Details
Executives
Chairman and Venture Partner
H. Robert Horvitz
Director Operations and Legal Affairs
Dana K. O'Brien